EUVIMEDEUVIMED entdecken
Fallbericht

An Inflammatory Myofibroblastic Tumor With a Novel ALK V1180L Mutation Leading to Acquired Resistance to Tyrosine Kinase Inhibitors

Brittney Sharpe, Donald C Green, Laura J Tafe, Garrett T Wasp, Darcy A Kerr, Nooshin K Dashti

Genes, Chromosomes and Cancer · 2024

DOI: 10.1002/gcc.70012 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Genes, Chromosomes and Cancer, 2024. Verfasst von Brittney Sharpe und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of West Indies, Mona, Jamaica. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Protein Kinase Inhibitors, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm that can locally recur and potentially metastasize. Approximately 50% of IMTs harbor rearrangements in the gene encoding anaplastic lymphoma kinase ( ALK ), a receptor tyrosine kinase that can be therapeutically targeted with tyrosine kinase inhibitors (TKIs). With successful application of TKI in ALK‐positive nonsmall cell carcinoma (NSCLC), ALK inhibitors are often first‐line treatments for patients with unresectable or metastatic IMTs. Although acquired resistance to these agents may develop, resistance mechanisms are sparsely reported for IMTs. Here we report a case of a 71 year‐old man with metastatic pulmonary IMT harboring a DCTN1::ALK fusion that progressed during alectinib TKI treatment. Whole exome sequencing of an enlarging metastatic lesion in right 4th rib revealed a novel p.V1180L mutation in the ALK tyrosine kinase domain as the mechanism of acquired resistance. To our knowledge, this is the first report of acquired p. V1180L mutation in IMTs treated with TKIs. In cases of ALK‐positive IMTs that progress on TKI therapy, targeted sequencing for acquired ALK mutations may inform clinical decisions to adopt second‐line therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anaplastic Lymphoma KinaseProtein Kinase InhibitorsDrug Resistance, NeoplasmHumansMaleAgedPiperidinesMutationNeoplasms, Muscle TissueLung NeoplasmsCarbazolesTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

ALKDCTN1IMTTKIalectinibc.3538G>Cinflammatory myofibroblastic tumorp.V1180Lresistancetyrosine kinase inhibitor

Substanzen

Anaplastic Lymphoma KinaseProtein Kinase InhibitorsALK protein, humanalectinibPiperidinesCarbazolesTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • University of West Indies, Mona, Jamaica.
  • Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
  • Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
  • Department of Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.

Zitieren

APA

Sharpe, B., Green, D. C., Tafe, L. J., Wasp, G. T., Kerr, D. A., & Dashti, N. K. (2024). An Inflammatory Myofibroblastic Tumor With a Novel ALK V1180L Mutation Leading to Acquired Resistance to Tyrosine Kinase Inhibitors. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.70012

Vancouver

Sharpe B, Green DC, Tafe LJ, Wasp GT, Kerr DA, Dashti NK. An Inflammatory Myofibroblastic Tumor With a Novel ALK V1180L Mutation Leading to Acquired Resistance to Tyrosine Kinase Inhibitors. Genes, Chromosomes and Cancer. 2024. doi:10.1002/gcc.70012

BibTeX
@article{Sharpe2024,
  author = {Sharpe, Brittney and Green, Donald C and Tafe, Laura J and Wasp, Garrett T and Kerr, Darcy A and Dashti, Nooshin K},
  title = {An Inflammatory Myofibroblastic Tumor With a Novel ALK V1180L Mutation Leading to Acquired Resistance to Tyrosine Kinase Inhibitors},
  journal = {Genes, Chromosomes and Cancer},
  year = {2024},
  doi = {10.1002/gcc.70012}
}
Kostenlos starten →